Huntoon, Catherine J <br/><br/>
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.  [electronic resource] 

 -  Cancer research  Jun 2013 
 - 3683-91 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-13-0110  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Ataxia Telangiectasia Mutated Proteins<br/>BRCA1 Protein--genetics<br/>BRCA2 Protein--genetics<br/>Benzimidazoles--pharmacology<br/>Cell Cycle Proteins--antagonists & inhibitors<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Checkpoint Kinase 1<br/>Cisplatin--pharmacology<br/>Deoxycytidine--analogs & derivatives<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Immunoblotting<br/>Ovarian Neoplasms--genetics<br/>Phosphorylation--drug effects<br/>Poly(ADP-ribose) Polymerase Inhibitors<br/>Poly(ADP-ribose) Polymerases--metabolism<br/>Protein Kinases--genetics<br/>Protein Serine-Threonine Kinases--antagonists & inhibitors<br/>Pyrazines--pharmacology<br/>Pyrazoles--pharmacology<br/>Pyrimidines--pharmacology<br/>RNA Interference<br/>Signal Transduction--drug effects<br/>Sulfones--pharmacology<br/>Topotecan--pharmacology<br/>cdc25 Phosphatases--genetics<br/>Gemcitabine